10/05/2024
5 years ago, I sat in a room with a couple friends - fellow biotechnology entrepreneurs (a PhD and an MD) - and we decided to try to find an opportunity to positively impact a new area of medicine, a "white space" where most start-ups would be crazy to go because of the size of the challenges ahead.
We had all been impacted directly or indirectly by someone who had Lyme disease. We knew the diagnosis was challenging, the medicines are generic (not built for purpose), that the medicines might damage other parts of the patient, and that no one knew why some people failed treatment and ended up with Long Lyme, etc. But we needed a scientist with vision and a high potential drug candidate to advance. We eventually found Kim Lewis, PhD, Head of Antimicrobial Discovery at Northeastern University and convinced him to join us.
Today, Kim's (and his lab mate Nadja Leimer's) discoveries have made it to human clinical studies. This herculean lift from the benchtop in a Boston lab to human clinical trials sponsored by our company, Flightpath Biosciences, and supported by all three major Lyme Foundations, is an enormous accomplishment for his team, our team, our company and our supporters.
We are now a clinical-stage biopharmaceutical company and so excited for the next 5 years.
Please see our announcement here:
https://www.accesswire.com/861782/flightpath-biosciences-begins-human-clinical-testing-of-the-worlds-first-narrow-spectrum-antibiotic-targeting-lyme-disease
